Works matching IS 25233548 AND DT 2021 AND VI 41 AND IP 9

Results: 10

Front Cover: Nuclear Aurora kinase A triggers programmed death‐ligand 1‐mediated immune suppression by activating MYC transcription in triple‐negative breast cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. i, doi. 10.1002/cac2.12219

By:

Sun, Shulan;
Zhou, Wei;
Li, Xiaoxi;
Peng, Fei;
Yan, Min;
Zhan, Yajing;
An, Fan;
Li, Xiaoyan;
Liu, Yunyong;
Liu, Quentin;
Piao, Haozhe

Publication type:

Article

CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 925, doi. 10.1002/cac2.12201

By:

Deng, Wenhai;
Chen, Panpan;
Lei, Wen;
Xu, Yang;
Xu, Nengwen;
Pu, Jeffrey J.;
Liang, Aibin;
Qian, Wenbin

Publication type:

Article

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 921, doi. 10.1002/cac2.12199

By:

Zhou, Chengjing;
Jiang, Ting;
Li, Rongzhen;
Yuan, Yan;
Xie, Weihao;
Huang, Xiaoxue;
Wang, Qiaoxuan;
Chang, Hui;
Chen, Gong;
Li, Yuhong;
Zeng, Zhifan;
Xiao, Weiwei;
Gao, Yuanhong

Publication type:

Article

Nuclear Aurora kinase A triggers programmed death‐ligand 1‐mediated immune suppression by activating MYC transcription in triple‐negative breast cancer.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 851, doi. 10.1002/cac2.12190

By:

Sun, Shulan;
Zhou, Wei;
Li, Xiaoxi;
Peng, Fei;
Yan, Min;
Zhan, Yajing;
An, Fan;
Li, Xiaoyan;
Liu, Yunyong;
Liu, Quentin;
Piao, Haozhe

Publication type:

Article

Intra‐heterogeneity in transcription and chemoresistant property of leukemia‐initiating cells in murine Setd2<sup>−/−</sup> acute myeloid leukemia.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 867, doi. 10.1002/cac2.12189

By:

Song, Jiachun;
Du, Longting;
Liu, Ping;
Wang, Fuhui;
Zhang, Bo;
Xie, Yinyin;
Lu, Jing;
Jin, Yi;
Zhou, Yan;
Lv, Gang;
Zhang, Jianmin;
Chen, Saijuan;
Chen, Zhu;
Sun, Xiaojian;
Zhang, Yuanliang;
Huang, Qiuhua

Publication type:

Article

Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 830, doi. 10.1002/cac2.12183

By:

Li, Shu‐Jin;
Chen, Jia‐Xian;
Sun, Zhi‐Jun

Publication type:

Article

KDELR2 promotes breast cancer proliferation via HDAC3‐mediated cell cycle progression.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 904, doi. 10.1002/cac2.12180

By:

Wei, Haoran;
Ma, Wenhao;
Lu, Xiaofei;
Liu, Haiying;
Lin, Kashuai;
Wang, Yinghui;
Ye, Zijian;
Sun, Linchong;
Huang, Zhitong;
Pan, Tingting;
Zhou, Zilong;
Cheng, Eric Y.;
Zhang, Huafeng;
Gao, Ping;
Zhong, Xiuying

Publication type:

Article

Advancing to the era of cancer immunotherapy.

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 803, doi. 10.1002/cac2.12178

By:

Wang, Yun;
Wang, Min;
Wu, Hao‐Xiang;
Xu, Rui‐Hua

Publication type:

Article

Issue Information.

Published in:: Cancer Communications, 2021, v. 41, n. 9, p. 801, doi. 10.1002/cac2.12060
Publication type:: Article

Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial

Published in:

Cancer Communications, 2021, v. 41, n. 9, p. 889, doi. 10.1002/cac2.12179

By:

Shi, Yuankai;
Lei, Kaijian;
Jia, Yuming;
Ni, Bingqiang;
He, Zhiyong;
Bi, Minghong;
Wang, Xicheng;
Shi, Jianhua;
Zhou, Ming;
Sun, Qian;
Wang, Guolei;
Chen, Dongji;
Shu, Yongqian;
Liu, Lianke;
Guo, Zhongliang;
Liu, Yong;
Yang, Junquan;
Wang, Ke;
Xiao, Ke;
Wu, Lin

Publication type:

Article